Status:
RECRUITING
Histological Validation of dGEMRIC Indices as a Quantitative Biomarker for Cartilage Damage in the Hip Joint
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Conditions:
Cartilage Damage
Osteoarthritis, Hip
Eligibility:
All Genders
18+ years
Brief Summary
In this study, the investigators seek to validate 3D model-based dGEMRIC (delayed gadolinium enhanced MRI of cartilage) values against histologic grading of cartilage quality, using osteochondral samp...
Detailed Description
For patients with advanced hip joint degeneration visible on pelvic radiographs, joint-preserving surgery is often not an option, making joint replacement the primary treatment choice. However, for th...
Eligibility Criteria
Inclusion
- Patients with advanced hip osteoarthritis.
- Preoperative hip MRI including biochemical sequence (MP2RAGE).
- Indication for hip replacement.
Exclusion
- Patients without informed consent.
- Age under 18 years.
- Insufficient language understanding in German, French, or English.
- Previous hip surgeries.
- Neoplastic and inflammatory comorbidities of the hip.
- Post-traumatic or pediatric deformities.
- Avascular necrosis of the femoral head.
- Inadequate MRI image quality (motion artifacts, extra-articular contrast media administration, delay (\>45 minutes) between contrast injection and MRI imaging).
Key Trial Info
Start Date :
September 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT06185036
Start Date
September 1 2022
End Date
December 31 2025
Last Update
January 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Bern (Inselspital)
Bern, Switzerland, 3010